Acute Toxicity Studies on Secretome Derived from Umbilical Cord Blood Dendritic Cells in Rats by Different Dosaged Levels
7 affiliations
- 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung, Sumedang Km. 21, Jatinangor 45363, Indonesia. Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung, Sumedang Km. 21, Jatinangor 45363, Indonesia
- 2Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung, Sumedang Km. 21, Jatinangor 45363, Indonesia
- 3Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung, Sumedang Km. 21, Jatinangor 45363, Indonesia. PT Prodia StemCell Indonesia, D.K.I Jakarta 10430, Indonesia
- 4PT Prodia StemCell Indonesia, D.K.I Jakarta 10430, Indonesia
- 5Head and Neck Oncology Division ENT Department-Hasan Sadikin Hospital, Faculty of Medicine, Universitas Padjadjaran, Jl. Raya Bandung, Sumedang Km. 21, Jatinangor 45363, Indonesia
- 6iRATco Laboratory Services, Bogor 16680, Indonesia
- 7Veterinary Pathology Division, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor 16680, Indonesia
Abstract
Dendritic cells-derived umbilical cord blood monocytes were characterized by surface markers such as CD83, CD86, CD54, CD40, and HLA-DR, which are essential for T-cell activation. These cells produce a secretome that is rich in several types of proteins like cytokines, chemokines, and growth factors, showing potential therapeutic applications, especially in cancer treatment. To assess acute toxicity, a total of 30 female Sprague-Dawley rats (Rattus norvegicus) were randomly divided into six different groups (n = 5 rats per group) based on UCB-derived DCs Secretome concentrations (0.015%, 0.15%, 1%, 10%, 100%) and control group administered via intramuscular injection, followed by histopathological analysis of vital organs like liver, heart, spleen, kidney, and lungs was conducted in a 14-day period. The results revealed no mortality, adverse event signs, or significant pathological changes in any organs, indicating that the UCB-DCs secretome did not induce acute toxicity. This research concludes that UCB-derived DCs secretome is non-toxic at the tested dosage levels, affirming its safety for potential clinical use. These findings highlight the promise of UCB-DCs secretome as a therapeutic agent, particularly in oncology, and emphasize the need for further research, including randomized clinical trials, to explore its full potential in clinical settings.
Related
- Same Factor, Different Branches: Context-Dependent Control of Dendritic Development by Lhx2
- Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies
- Combining ability and gene action studies for different horticultural traits in pink brinjal (Solanum melongena L.)
- Remote Body Temperature Monitoring in Infectious Diseases: Pilot Studies in Different Artiodactyla Models.
- The Pseudomonas protegens PBL3 secretome exerts antimicrobial activity against Burkholderia glumae by disrupting cell envelope homeostasis and impairing bacterial replication
BibTeX
@article{sulistya2026acute,
title = {{Acute Toxicity Studies on Secretome Derived from Umbilical Cord Blood Dendritic Cells in Rats by Different Dosaged Levels}},
author = {Albertus Budi Sulistya and Keri Lestari and Cynthia Retna Sartika and Geofanny Facicilia and Rima Haifa and Nisa Zulfani and Cecilia Aileen Yap and Yussy Afriani Dewi and Elpita Tarigan and Yusa Irarang and Mawar Subangkit},
journal = {Hayati Journal of Biosciences},
year = {2026},
month = oct,
doi = {10.4308/hjb.33.6.1564-1574},
url = {https://doi.org/10.4308/hjb.33.6.1564-1574},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Acute Toxicity Studies on Secretome Derived from Umbilical Cord Blood Dendritic Cells in Rats by Different Dosaged Levels
AU - Albertus Budi Sulistya
AU - Keri Lestari
AU - Cynthia Retna Sartika
AU - Geofanny Facicilia
AU - Rima Haifa
AU - Nisa Zulfani
AU - Cecilia Aileen Yap
AU - Yussy Afriani Dewi
AU - Elpita Tarigan
AU - Yusa Irarang
AU - Mawar Subangkit
PY - 2026
DA - 2026/10/30
JO - Hayati Journal of Biosciences
DO - 10.4308/hjb.33.6.1564-1574
UR - https://doi.org/10.4308/hjb.33.6.1564-1574
AB - Dendritic cells-derived umbilical cord blood monocytes were characterized by surface markers such as CD83, CD86, CD54, CD40, and HLA-DR, which are essential for T-cell activation. These cells produce a secretome that is rich in several types of proteins like cytokines, chemokines, and growth factors, showing potential therapeutic applications, especially in cancer treatment. To assess acute toxicity, a total of 30 female Sprague-Dawley rats (Rattus norvegicus) were randomly divided into six different groups (n = 5 rats per group) based on UCB-derived DCs Secretome concentrations (0.015%, 0.15%, 1%, 10%, 100%) and control group administered via intramuscular injection, followed by histopathological analysis of vital organs like liver, heart, spleen, kidney, and lungs was conducted in a 14-day period. The results revealed no mortality, adverse event signs, or significant pathological changes in any organs, indicating that the UCB-DCs secretome did not induce acute toxicity. This research concludes that UCB-derived DCs secretome is non-toxic at the tested dosage levels, affirming its safety for potential clinical use. These findings highlight the promise of UCB-DCs secretome as a therapeutic agent, particularly in oncology, and emphasize the need for further research, including randomized clinical trials, to explore its full potential in clinical settings.
SN - 1978-3019
SN - 2086-4094
ER -